October 1, 2012Open Access

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. (Funded by F. Hoffmann-La Roche/Genentech; EMILIA ClinicalTrials.gov number, NCT00829166.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Sunil Verma

David Miles

Luca Gianni

Journals

New England Journal of Medicine

Actions

Institutions

Massachusetts General Hospital

Dana-Farber Cancer Institute

Duke Medical Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider